HVB MINI FUTURE BULL - ASTRAZENECA | Delayed Deutsche Boerse AG 08:55:52 19/06/2024 BST | ||
| 5.06 EUR | -4.89% |
|
| 1 month | +7.26% | ||
| 3 months | +77.93% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 19/06/24 | 5.06 | -4.89% |
| 18/06/24 | 5.32 | -0.93% |
| 17/06/24 | 5.37 | -2.19% |
| 14/06/24 | 5.49 | +3.00% |
| 13/06/24 | 5.33 | -1.48% |
Delayed Quote Deutsche Boerse AG
Last update June 19, 2024 at 08:55 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HR70UN |
| ISIN | DE000HR70UN8 |
| Date issued | 23/04/2021 |
| Strike | 7,904 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.78 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.68 € |
|---|---|
| Lowest since issue | 0.49 € |
| Spread | 0.01 € |
| Spread % | 0.19% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.5
USD
Average target price
174.4
USD
Spread / Average Target
+10.73%
- Stock Market
- Certificates
- Certificat